reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Arch Therapeutics, Inc.

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$4Mstalepublic float
2025-05-23most recent failure
2025-05-23filed for bankruptcy

Score over time

01234202220232024202520262022-01-01 · score 12021-12-08 auditor change2022-04-01 · score 12021-12-08 auditor change2022-07-01 · score 12021-12-08 auditor change2022-10-01 · score 12021-12-08 auditor change2023-07-01 · score 12023-05-16 filed late (10-Q) · XBRL or exhibits2023-10-01 · score 12023-05-16 filed late (10-Q) · XBRL or exhibits2024-01-01 · score 22023-12-29 filed late (10-K) · auditor2023-05-16 filed late (10-Q) · XBRL or exhibits2024-04-01 · score 42024-02-15 filed late (10-Q)2024-01-12 auditor change2023-12-29 filed late (10-K) · auditor2023-05-16 filed late (10-Q) · XBRL or exhibits2024-07-01 · score 32024-02-15 filed late (10-Q)2024-01-12 auditor change2023-12-29 filed late (10-K) · auditor2024-10-01 · score 42024-08-14 filed late (10-Q) · accounts not ready2024-02-15 filed late (10-Q)2024-01-12 auditor change2023-12-29 filed late (10-K) · auditor2025-01-01 · score 42024-12-31 filed late (10-K) · auditor2024-08-14 filed late (10-Q) · accounts not ready2024-02-15 filed late (10-Q)2024-01-12 auditor change2025-04-01 · score 22024-12-31 filed late (10-K) · auditor2024-08-14 filed late (10-Q) · accounts not ready2025-07-01 · score 32025-05-23 auditor change2024-12-31 filed late (10-K) · auditor2024-08-14 filed late (10-Q) · accounts not ready2025-10-01 · score 22025-05-23 auditor change2024-12-31 filed late (10-K) · auditor2026-01-01 · score 12025-05-23 auditor change2026-04-01 · score 12025-05-23 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Arch Therapeutics, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended September 30, 2024 by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the year ended September 30, 2024 by the prescribed due date. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete the Form 10-K and in order to permit the Company’s independent registered public accounting firm to complete its review. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company’s Annual Report on Form 10-K for the year ended September 30, 2024 will be filed on or before the 15th calendar day following the prescribed due date

NT 10-K, filed 2024-12-31 · auditor

What it filed

2025-05-23auditor changed or resigned SEC →

2024-12-31filed late (10-K)auditor SEC →

Arch Therapeutics, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended September 30, 2024 by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the year ended September 30, 2024 by the prescribed due date. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete the Form 10-K and in order to permit the Company’s independent registered public accounting firm to complete its review. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company’s Annual Report on Form 10-K for the year ended September 30, 2024 will be filed on or before the 15th calendar day following the prescribed due date

2024-08-14filed late (10-Q)accounts not ready SEC →

Arch Therapeutics, Inc. (the “Registrant”) has been delayed in filing its Quarterly Report on Form 10-Q (the “Quarterly Report”) for the nine months ended June 30, 2024, due to a delay in the compilation, dissemination and review of the information required to be presented by the Registrant in the Quarterly Report, which has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without unreasonable effort or expense. The Registrant expects to file the Quarterly Report on or before August 19, 2024

2024-02-15filed late (10-Q) SEC →

Arch Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 by the prescribed due date. Additional time was needed for the Company to file its Annual Report on Form 10-K for the year ended September 30, 2023, which was just filed on February 14, 2024, and this has delayed the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 will be filed on or before the 5th calendar day following the prescribed due date

2024-01-12auditor changed or resigned SEC →

2023-12-29filed late (10-K)auditor SEC →

Arch Therapeutics, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended September 30, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the year ended September 30, 2023 by the prescribed due date. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete the Form 10-K and in order to permit the Company’s independent registered public accounting firm to complete its review. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Company's Annual Report on Form 10-K for the year ended September 30, 2023 will be filed on or before the 15th calendar day following the prescribed due date

2023-05-16filed late (10-Q)XBRL or exhibits SEC →

Arch Therapeutics, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 by the prescribed due date without unreasonable effort or expense because of the circumstances described below. The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, cannot be filed within the prescribed time period because the Company requires additional time for compilation and review to insure adequate disclosure of certain information required to be included in the Quarterly Report on Form 10-Q, including the XBRL (eXtensible Business Reporting Language) Interactive Data Files for the financial statements and notes included in the Quarterly Report. The Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 will be filed on or before the 5th calendar day following the prescribed due date

2021-12-08auditor changed or resigned SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com